However, only about 3% had at least one claim in 2022
This is why continuing PlexusDx treatment on a consistent schedulewithout gaps between dosesmaximizes sustained appetite control and metabolic benefits over time
In clinical studies of the FDA-approved tirzepatide products (Mounjaro and Zepbound), patients experienced significant reductions in body weight and improvements in metabolic markers when the medication was combined with diet and physical activity
However, consumers should be cautious and critical of these claims, as many products are not as healthy as they appear
However, discontinuation of semaglutide in extension studies was associated with partial weight regain, underscoring the chronic nature of obesity and the likely need for ongoing pharmacotherapy to sustain benefits
Your treatment starts with in-office lab work, a consultation with our OB/GYN provider, and a hormone plan built specifically around your results and goals